Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
654.4(c) 636.53(c) 630.59(c) 634(c) 635.16(c) Last
700 393 1 277 301 732 074 563 827 637 304 Volume
+1.72% -2.73% -0.93% +0.54% +0.18% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 15 430 M - -
Net income 2021 7 903 M - -
Net cash position 2021 5 814 M - -
P/E ratio 2021 9,08x
Yield 2021 -
Sales 2022 12 561 M - -
Net income 2022 4 769 M - -
Net cash position 2022 11 197 M - -
P/E ratio 2022 14,2x
Yield 2022 -
Capitalization 66 409 M 66 409 M -
EV / Sales 2021 3,93x
EV / Sales 2022 4,40x
Nbr of Employees 9 766
Free-Float 81,9%
More Financials
Company
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis,... 
Sector
Biotechnology & Medical Research
Calendar
12/11 | 12:45pmPresentation
More about the company
Ratings of Regeneron Pharmaceuticals
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about REGENERON PHARMACEUTICALS
12/03Regeneron to Participate in H.C. Wainwright & Co. Virtual Event
PR
12/03Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LL..
AQ
12/02What COVID-19 vaccine and drug makers have to say about Omicron
RE
12/02MarketScreener's World Press Review - December 2, 2021
11/30Officials offer vaccine reassurance; WHO advises against travel bans
RE
11/30US Stocks Slump as Omicron Variant, Fed Chief's Comment on Faster Asset Purchase Taperi..
MT
11/30CLOSE UPDATE : US Stocks See Sharp Decline as Omicron Variant, Fed Chief Comment on Faster..
MT
11/30Yen, Swiss franc rally on global outlook risks after hawkish Powell
RE
11/30ANALYSIS : As Omicron plays havoc with markets, shares of vaccine makers surge
RE
11/30Wall St sinks as taper acceleration worries pile onto virus angst
RE
11/30Pharmaceutical Names to See Increased Volatility into Year End Amid Omicron Updates, Op..
MT
11/30Equities Drop Midday as Moderna CEO Questions COVID-19 Vaccines' Efficacy Against Omicr..
MT
11/30MIDDAY REPORT : US Stocks Drop as Moderna CEO Questions COVID-19 Vaccines' Efficacy Agains..
MT
11/30US Stocks Drop as Moderna CEO Warns on Efficacy of COVID-19 Vaccines Against Omicron; O..
MT
11/30Wall St drops over 1% on Powell's faster taper comments, Omicron worries
RE
More news
News in other languages on REGENERON PHARMACEUTICALS
12/02PLANÈTE BOURSE : La revue de presse du jeudi 2 décembre 2021
12/02GSK dice che test su farmaco ad anticorpi mostrano efficacia contro Omicron
12/02GlaxoSmithKline-Antikörpercocktail in Labortests gegen Omikron aktiv
11/30Les actions américaines chutent en raison de la variante Omicron et du commentaire du c..
11/30CLOSE UPDATE : Les actions américaines connaissent une forte baisse alors que la variante ..
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 635,16 $
Average target price 697,52 $
Spread / Average Target 9,82%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS31.23%66 409
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819
BEIGENE, LTD.36.22%32 284